Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zevra Therapeutics Inc. (ZVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/12/2025: ZVRA (3-star) is a STRONG-BUY. BUY since 21 days. Profits (15.11%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $21.71
Year Target Price $21.71
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.33% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 492.12M USD | Price to earnings Ratio - | 1Y Target Price 21.71 |
Price to earnings Ratio - | 1Y Target Price 21.71 | ||
Volume (30-day avg) - | Beta 1.99 | 52 Weeks Range 4.20 - 9.76 | Updated Date 06/30/2025 |
52 Weeks Range 4.20 - 9.76 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -226.64% | Operating Margin (TTM) -26.28% |
Management Effectiveness
Return on Assets (TTM) -27.73% | Return on Equity (TTM) -204.78% |
Valuation
Trailing PE - | Forward PE 5.46 | Enterprise Value 491322769 | Price to Sales(TTM) 12.12 |
Enterprise Value 491322769 | Price to Sales(TTM) 12.12 | ||
Enterprise Value to Revenue 12.11 | Enterprise Value to EBITDA -4.24 | Shares Outstanding 54679600 | Shares Floating 45985578 |
Shares Outstanding 54679600 | Shares Floating 45985578 | ||
Percent Insiders 0.74 | Percent Institutions 65.39 |
Analyst Ratings
Rating 4.57 | Target Price 21.71 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zevra Therapeutics Inc.
Company Overview
History and Background
Zevra Therapeutics, formerly KemPharm, Inc., was founded in 2006. Initially focused on prodrug approaches to known pharmaceuticals, it evolved into a rare disease company, marked by acquisitions and strategic shifts.
Core Business Areas
- Rare Disease Therapeutics: Development and commercialization of therapies for rare diseases. Their primary focus is on treatments for rare neurological and metabolic disorders.
Leadership and Structure
Richard J. West is the CEO. The company operates with a typical biotech organizational structure, including research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- OLPUDIC (sodium phenylbutyrate): A treatment for urea cycle disorders (UCDs). Approved by the FDA. Zevra estimates about 2,100 patients in the US suffer from UCDs. Revenue data not publicly available in specific breakdown. Competitors include BUPHENYL (Horizon Therapeutics) and RAVICTI (Horizon Therapeutics).
- AZSTARYS (dexmethylphenidate and serdexmethylphenidate): A treatment for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. It has been licensed to Corium, Inc.. Royalty revenue from sales of this product. AZSTARYS generated $21.4M in royalties for Zevra in 2023. Competitors include Concerta, Ritalin, Adderall, Vyvanse, and other ADHD medications.
Market Dynamics
Industry Overview
The rare disease therapeutics market is characterized by high unmet needs, regulatory incentives (e.g., orphan drug designation), and potential for premium pricing. It's a growing sector driven by increased awareness and improved diagnostics.
Positioning
Zevra Therapeutics is positioned as a specialty pharmaceutical company focused on rare diseases. Its competitive advantage lies in its targeted therapies and orphan drug status for OLPUDIC.
Total Addressable Market (TAM)
The global rare disease market is estimated to be several billion dollars. Zevra is positioned to capture a share of the UCD and ADHD markets, through OLPUDIC and AZSTARYS, respectively.
Upturn SWOT Analysis
Strengths
- FDA-approved products (OLPUDIC, AZSTARYS)
- Focus on rare diseases with unmet needs
- Strategic partnerships (e.g., Corium)
- Royalty revenue stream from AZSTARYS
Weaknesses
- Limited product portfolio
- Reliance on strategic partners for commercialization
- Smaller company relative to major pharmaceutical firms
- History of losses
Opportunities
- Expanding the OLPUDIC label to include additional UCD patient populations
- Acquiring or licensing additional rare disease assets
- Geographic expansion
- Potential for pipeline growth
Threats
- Competition from existing and emerging therapies
- Regulatory challenges
- Patent expirations
- Reimbursement pressures
Competitors and Market Share
Key Competitors
- HZNP
- TEVA
Competitive Landscape
Zevra is smaller than HZNP and TEVA, therefore Zevra focuses on specific niche markets within rare diseases. HZNP has broader orphan drug portfolio. TEVA is a large generic pharmaceutical company.
Major Acquisitions
Avenue Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Expanded product portfolio to include IV Tramadol
SERB Pharmaceutical's US rights for UCD product
- Year: 2023
- Acquisition Price (USD millions): 135
- Strategic Rationale: Acquired US rights for OLPUDIC for UCD patients.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth is hard to get in a short period of time. Need more time.
Future Projections: Future Projections are hard to get in a short period of time. Need more time.
Recent Initiatives: Recent strategic initiatives include the commercial launch of OLPUDIC and efforts to maximize royalty revenue from AZSTARYS.
Summary
Zevra Therapeutics is a specialty pharmaceutical company focused on rare diseases. Its strengths include approved products and strategic partnerships. Weaknesses include a limited portfolio and reliance on partners. The company is focused on growing OLPUDIC market share and maximizing royalty revenue. Competition and regulatory hurdles represent ongoing threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Publicly Available Financial Data
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zevra Therapeutics Inc.
Exchange NASDAQ | Headquaters Celebration, FL, United States | ||
IPO Launch date 2015-04-16 | President, CEO & Director Mr. Neil F. McFarlane | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://zevra.com |
Full time employees 59 | Website https://zevra.com | ||
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.